Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Orchestra BioMed Holdings, Inc.

NASDAQ: OBIO · Industrial Applications and Services · 9 alerts · CIK 1814114

Share price
$7.12Close, Nov 16
Market cap
$560M
Shares outstanding
78.7MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Orchestra BioMed Holdings, Inc. filings on SEC EDGAR ↗

4:28 PM ET Form 4
Insider Buying

Orchestra BioMed Holdings 10% Owner Rtw Investments LP Buys $6M of Stock

Rtw Investments LP, 10% Owner, bought 1,200,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $6M in total on Nov 9, 2026. Shares held after the trade: 10,756,063 (+12.6%).

Value
$6M
Shares
1,200,000
Price
$5.00
Role
10% Owner
Holding change
+12.6%
Trade date
Nov 9, 2026
4:05 PM ET 10-Q
Financial Results

Orchestra BioMed Holdings Q3 2026 Results: Net Loss of $18.8M, Loss Narrows

Orchestra BioMed reported a significant decrease in total revenue to $0.29 million for the nine months ended September 30, 2026, compared to $2.57 million in the prior year, primarily due to the absence of partnership revenue. The company's total stockholders' equity declined from $53.6 million to $7.8 million as the accumulated deficit reached $425.8 million.

Key figure
Net loss $18.8M
4:32 PM ET Form 4
Insider Buying

Orchestra BioMed Holdings Insider Eric S. Fain Buys $100K of Stock

Eric S. Fain bought 20,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 119,630 (+20.1%).

Value
$100K
Shares
20,000
Price
$5.00
Holding change
+20.1%
Trade date
Nov 9, 2026
4:32 PM ET Form 4
Insider Buying

Orchestra BioMed Holdings Insider David Pacitti Buys $100K of Stock

David Pacitti bought 20,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 74,750 (+36.5%).

Value
$100K
Shares
20,000
Price
$5.00
Holding change
+36.5%
Trade date
Nov 9, 2026
4:32 PM ET Form 4
Insider Buying

Orchestra BioMed Holdings Insider David P. Hochman Buys $25K of Stock

David P. Hochman bought 5,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $25K in total on Nov 9, 2026. Shares held after the trade: 437,916 (+1.2%).

Value
$25K
Shares
5,000
Price
$5.00
Holding change
+1.2%
Trade date
Nov 9, 2026
4:16 PM ET 8-K
Capital Raise

Orchestra BioMed Holdings Capital Raise of $86.3M

Orchestra BioMed closed an underwritten public offering of 17,250,000 shares of common stock, which included the full exercise of the underwriters' over-allotment option. The offering was priced at $5.00 per share, generating gross proceeds of approximately $86.3 million. The company intends to use the funds to support its AVIM Therapy and Virtue SAB clinical programs, including the BACKBEAT global pivotal trial.

Value
$86.3M
Counterparty
Piper Sandler & Co.
5:15 PM ET Form 4
Insider Selling

Orchestra BioMed Holdings Insider Darren Sherman Sells $86.1K of Stock

Darren Sherman sold 15,000 shares of Orchestra BioMed Holdings, Inc. at $5.74 a share, worth $86.1K in total on Nov 2, 2026. Shares held after the trade: 1,104,402 (-1.3%).

Value
$86.1K
Shares
15,000
Price
$5.74
Holding change
-1.3%
Trade date
Nov 2, 2026
4:32 PM ET Form 4
Insider Selling

Orchestra BioMed Holdings Insider Darren Sherman Sells $95.4K of Stock

Darren Sherman sold 15,000 shares of Orchestra BioMed Holdings, Inc. at $6.36 a share, worth $95.4K in total on Oct 1, 2026. Shares held after the trade: 1,119,402 (-1.3%).

Value
$95.4K
Shares
15,000
Price
$6.36
Holding change
-1.3%
Trade date
Oct 1, 2026
8:15 AM ET 8-K
Business Update

Orchestra BioMed Holdings Business Update

Orchestra BioMed exceeded its enrollment target for the BACKBEAT Global Pivotal Trial, randomizing 330 patients across 81 sites globally. The trial is evaluating AVIM Therapy for uncontrolled hypertension in pacemaker patients in collaboration with Medtronic. The company expects to submit primary endpoint data for presentation at a major cardiovascular conference in Q2 2027.

Counterparty
Medtronic plc

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.